I looked at Insmed's site and this is from an Investor News Release first qtr. It seems it depends on the country and their approval dates. In US, it looks like just after approval.
"
In February 2025, the FDA accepted the Company's New Drug Application (NDA) for brensocatib for patients with bronchiectasis, granting the application Priority Review designation with a Prescription Drug User Fee Act (PDUFA) target action date of August 12, 2025. If approved, Insmed expects to immediately launch brensocatib in the U.S.
Regulatory submissions for brensocatib in the EU and UK have been accepted, with submission in Japan planned for 2025. Insmed anticipates commercial launches for each territory in 2026, pending approval."
https://investor.insmed.com/2025-05-08-Insmed-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Update?printable=1